Lisa Broxmeyer

Lisa Broxmeyer

Auto-generated profile, based on publicly available information

Lisa Broxmeyer

Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
SSSam Schulman
Sam Schulman
MSMichelle Sholzberg
Michelle Sholzberg
Alex C SpyropoulosAlex C Spyropoulos
Alex C Spyropoulos
RZRyan Zarychanski
Ryan Zarychanski
HRHelaine E. Resnick
Helaine E. Resnick
IHInternational Society on Thrombosis and Haemostasis
International Society on Thrombosis and Haemostasis

18 March 2024 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
SSSam Schulman
Sam Schulman
DADonald M. Arnold
Donald M. Arnold
CBCharlotte A. Bradbury
Charlotte A. Bradbury
LBLisa Broxmeyer
Lisa Broxmeyer
JCJean Connors
Jean Connors
Alex C SpyropoulosAlex C Spyropoulos
Alex C Spyropoulos
Based on emerging evidence from the COVID-19 pandemic, the International Society on Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 were published in 2022. Since then, at least 16 new randomized controlled trials have contributed additional evidence, which necessitated a modification of most of the previous recommendations. We used again the American College of Cardiology Foundation/American Heart Association methodology for assessment of level of evidence (LOE) and class of recommendation (COR). Five recommendations had the LOE upgraded to A and 2 new recommendations on antithrombotic treatment for patients with COVID-19 were added. Furthermore, a section was added to answer questions about COVID-19 vaccination and vaccine-induced immune thrombotic thrombocytopenia (VITT), for which studies have provided some evidence. We only included recommendations with LOE A or B. Panelists agreed on 19 recommendations, 4 for nonhospitalized, 5 for noncritically ill hospitalized, 3 for critically ill hospitalized, and 2 for postdischarge patients, as well as 5 for vaccination and VITT. A strong recommendation (COR 1) was given for (a) use of prophylactic dose of low-molecular-weight heparin or unfractionated heparin in noncritically ill patients hospitalized for COVID-19, (b) for select patients in this group, use of therapeutic-dose low-molecular-weight heparin/unfractionated heparin in preference to prophylactic dose, and (c) for use of antiplatelet factor 4 enzyme immunoassays for diagnosing VITT. A strong recommendation was given against (COR 3) the addition of an antiplatelet agent in hospitalized, noncritically ill patients. These international guidelines provide recommendations for countries with diverse healthcare resources and COVID-19 vaccine availability.